India's Venus Remedies jumps after marketing authorization in Philippines
** Venus Remedies VENR.NS rises 7.8% to 348.30 rupees
** Pharmaceutical co secures marketing authorization for
Pemetrexed 500 mg in Philippines
** Pemetrexed is a chemotherapeutic agent widely used in
treatment of lung cancer and mesothelioma
** Trading vols at 65,031, 1.8x the 30-day avg
** Stock tims YTD losses to ~14%
(Reporting by Vijay Malkar)
((VijayDattaram.Malkar@thomsonreuters.com;))
Recent news on Venus Remedies
See all newsBrief: Venus Remedies Sept-Quarter Consol Net Profit 256.5 Million Rupees
Brief: Venus Remedies Secured Five Marketing Authorisations Across Kazakhstan, Peru, Kuwait And Argentina
India's Venus Remedies rises after quarterly profit more than doubles
Brief: Venus Remedies June-Quarter Consol Net Profit 229.7 Million Rupees
India raises price cap on cancer drugs to tackle shortage